Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

22.29 -1.33 (-5.63%)
Streaming Delayed Price Updated: 12:02 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Shares of Hims & Hers are falling even as the company has been posting some solid results. 
Via The Motley Fool
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children... 
Via Benzinga
Exposures Product Safety
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Is Hims & Hers Health Stock a Buy?
The risk-reward proposition is pretty one-sided here. 
Via The Motley Fool
Is Hims & Hers Health Stock a Buy?
The stock has been a strong performer this year, but the best could be yet to come. 
Via The Motley Fool
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June. 
Via The Motley Fool
Four Stocks To Watch This Week - Monday, Sept 9
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. 
Via Talk Markets
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
There is something for everybody in America's $4.5 trillion healthcare market. 
Via The Motley Fool
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Sales growth could accelerate now that it provides lower-cost, weight-management drugs. 
Via The Motley Fool
The Latest Analyst Ratings For Hims & Hers Health
Via Benzinga
Looking Into Hims & Hers Health's Recent Short Interest
Via Benzinga
Hims & Hers Health Unusual Options Activity For August 13
Via Benzinga
2 No-Brainer Growth Stocks to Buy With $200 Right Now
These businesses are rapidly growing profits and cash flows. 
Via The Motley Fool
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Hims & Hers Health Stock Was Falling This Week
A new threat from Eli Lilly pushed the stock lower. 
Via The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
Could a competitor lowering prices eat into Hims & Hers market share? 
Via The Motley Fool
Why Hims & Hers Health Stock Is Falling
Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has raised concerns over increased competition and potential market share loss. 
Via Benzinga
American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential. 
Via Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its... 
Via Benzinga
2 Magnificent Stocks That Are Screaming Buys in August
These companies aren't slowing down. 
Via The Motley Fool
Is Hims & Hers Health the Best Growth Stock for You?
Wall Street is missing the forest for the trees, and the opportunity is enormous. 
Via The Motley Fool
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
A company's investments can easily ruin the plans of its competitors. 
Via The Motley Fool
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last week 
Via MarketBeat
Topics Stocks
Exposures US Equities
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
Growth is set to accelerate starting next quarter, powered by its GLP-1 offering. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.